Distinct Hypoxia-Related Gene ProfilingCharacterizesClinicopathological Features and Immune Status ofMismatchRepair-Deficient Colon Cancer

Yixin Xu,1,2 Junjie Hu,4 Can Cao,2 Mili Zhang,2 Youdong Liu,2 Haonan Chen,1 ShanShan Wei,2 Ziyang Zhu,2 Yuqin Yang,5 Liang Yu,1,2 and Jikun Li1,2

1Department of General Surgery, Shanghai General Hospital of Nanjing Medical University, Shanghai, China
2Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3Department of General Surgery, Wujin Hospital Affiliated with Jiangsu University, The Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu, China
4Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
5Department of Laboratory Animal Centre, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Correspondence should be addressed to Liang Yu; liang.yu@shgh.cn and Jikun Li; jkli65975@163.com

Received 18 October 2021; Revised 7 November 2021; Accepted 13 November 2021; Published 7 December 2021

Academic Editor: Jimei Wang

Copyright © 2021 Yixin Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Despite dramatic responses to immune checkpoint inhibitors (ICIs) in patients with colon cancer (CC) harboring deficient mismatch repair (dMMR), more than half of these patients ultimately progress and experience primary or secondary drug resistance. XZ_here is no useful biomarker that is currently validated to accurately predict this resistance or stratify patients who may benefit from ICI-based immunotherapy. As hypoxic and acidic tumor microenvironment would greatly impair tumor-suppressing function of tumor-infiltrating lymphocytes (TILs), we sought to explore distinct immunological phenotypes by analysis of the intratumoral hypoxia state using a well-established gene signature. Based on the Gene Expression Omnibus (GEO) (n = 88) and The Cancer Genome Atlas (TCGA) (n = 49) databases of patients with CC, we found that dMMR CC patients could be separated into normoxia subgroup (NS) and hypoxia subgroup (HS) with different levels of expression of hypoxia-related genes (lower in NS group and higher in HS group) using NMF package. Tumoral parenchyma in the HS group had a relatively lower level of immune cell infiltration, particularly CD8+ T cells and M1 macrophages than the NS group, and coincided with higher expression of immune checkpoint molecules and C-X-C motif chemokines, which might be associated with ICI resistance and prognosis. Furthermore, three genes, namely, MT1E, MT2A, and MAFF, were identified to be differentially expressed between NS and HS groups in both GEO and TCGA cohorts. Based on these genes, a prognostic model with stable and valuable predicting ability has been built for clinical application. In conclusion, the varying tumor-immune microenvironment (TIME) classified by hypoxia-related genes might be closely associated with different therapeutic responses of ICIs and prognosis of dMMR CC patients.

1. Introduction

Colon cancer (CC) is the most prevalent type of malignancy worldwide, resulting in the fifth leading cause of death in 2020 [1]. The standard therapeutic procedures for advanced CC are surgery plus adjuvant therapy or neoadjuvant therapy. However, from 2018 to 2021, the death rate of patients with advanced disease has almost not changed [1, 2]. One of the molecular subtypes of CC, characterized by higher tumor mutational burden (TMB), more neoantigens,
and relatively favorable outcomes, is deficient mismatch repair (dMMR). A previous clinical trial demonstrated that metastatic patients with CC with dMMR tumors exhibited impressive and deep pathological responses to ICI-based immunotherapy [3]. However, approximately 60% of dMMR patients may still progress and experience resistance to the same regimens [4]. Thus, many studies have focused on conducting comprehensive genome-wide analysis to identify the underlying molecular mechanisms of poor response to ICIs and distinct outcomes in other types of human malignancy [5–7].

Some studies reported that higher level of TMB and large production of neoantigens were closely associated with the infiltration of immune cells and thus the response rate to immunotherapy [8], whereas many factors, such as restrained oxygen and nutrients, may impact tumor-infiltrating lymphocytes (TILs), leading to diverse and complex TME [9, 10]. One major player significantly influences many types of cells in TME is hypoxia. Although hypoxia is considered a hallmark of TME, it is widely known as a suppressor for immune cell metabolism and a promoter for tumor development and progression [11, 12]. Tumors and those tumor promoters deprive of oxygen and nutrient and subsequently produce hypoxia and acidic TME, which restrain the function of those TILs [13]. For example, the increased expression of lactic acid, which is the typical feature of hypoxia TME, plays an important immunosuppressive role by restraining the metabolism of TILs and thus inhibits the production of interferon-γ (IFN-γ) [14, 15]. Besides, another enriched expressed factor in hypoxia TME, named hypoxia-inducible factor-1α (HIF-1α), impairs the proliferation, migration, and cytotoxic function of CD8+ T cells by promoting them to a glycolytic phenotype [16].

In this study, based on the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases, we have investigated the role of hypoxia that acted in the tumor-immune microenvironment (TIME) of patients with CC with dMMR. Using hypoxia-related gene signature, we have classified dMMR patients into 2 subgroups and evaluated their different TIMEs. Moreover, we have also developed a prognostic model for dMMR CC patients in clinical application.

2. Materials and Methods

2.1. Datasets for Molecular Classification and Validation. The microarray data of 88 dMMR CC patients were collected from GSE39084 (16) and GSE39582 (72), which belonged to the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/). Because the number of dMMR CC patients was not enough for analysis, we merged both datasets after the batch effect was eliminated using limma (version 3.48.1) and sva (version 3.40.0) packages. Meanwhile, data of 49 dMMR CC patients for validation were obtained from The Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov/) using GDC API tools on July 7, 2021.

2.2. Hypoxia-Related Gene List. This list contained 200 hypoxia-related genes, which were accessed from the HALLMARK_HYPOXIA gene set of the Gene Set Enrichment Analysis (GSEA) database (http://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_HYPOXIA.html) [17, 18]. The complete gene list was contained in Table S1.

The immune-related genes were obtained from the Tracking Tumor Immunophenotype database (http://bioccs.hrbmu.edu.cn/TIP/index.jsp) [19]. This list contained negative, positive, T cell, CD8+ T cell, CD4+ T cell, dendritic cell, eosinophil, macrophage, monocyte, neutrophil, nature kill (NK) cell, Th1 cell, Th17 cell, Th 2 cell, Th22 cell, and Treg cell-correlated genes.

2.3. Procedure of Clustering Analysis. First, we used univariate Cox analysis to identify the prognostic value of hypoxia-related genes. Then, genes with \( p < 0.05 \) were chosen for subsequent analysis. The combined gene set, which contained 88 dMMR CC patients, was clustered using an unsupervised nonnegative matrix factorization (NMF) (version 0.23.0) package [20]. The optimal clustering number was chosen according to the \( k \) value when the cophenetic correlation coefficient started to decline. Then, the clustering result was evaluated using principal component analysis (PCA) and t-distributed stochastic neighbor embedding (t-SNE). Meanwhile, the overall survival (OS) of different subgroups was evaluated according to the result of the Kaplan–Meier analysis that was performed using the survival (3.2–11) package. Moreover, the clustering method according to hypoxia-related genes was validated using the TCGA COAD cohort.

2.4. Identification of Differentially Expressed Genes and Functional Annotation Analysis. Differentially expressed genes (DEGs) with FDR < 0.05 and |log 2 FC| > 1 were identified between 2 different subgroups using limma (version 3.48.1) package. Moreover, the functions according to DEGs were evaluated through the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) using clusterProfiler (version 4.0.2), topGO (version 2.44.0), and pathview (version 1.32.0) packages.

2.5. Evaluation of Tumor-Immune Microenvironment. To investigate the differences in TIME between the 2 subgroups, we used CIBERSORTx to estimate the infiltration of 22 different immune cells (https://cibersortx.stanford.edu/) [21]. Meanwhile, we also extracted the expressions of immune checkpoint molecules and CXC chemokines from microarray data of GEO sets and RNA-seq data of the TCGA cohort. The expressions of these variates were compared between different subgroups using the Wilcoxon test.

2.6. Construction of Prognostic Model Based on Prognostic Hypoxia-Related Genes. After molecular clustering, we built a prognostic model based on 2 hypoxia-related hub genes, which were the intersection of the GEO-DEGs and TCGA-DEGs using the least absolute shrinkage and selection
3. Results

3.1. Different Characteristics between Different Molecular Subgroups. The complete pipeline of this study is shown in Figure 1. Initially, we filtered 22 genes that were associated with the prognosis of dMMR patients from the 200 hypoxia-related gene list obtained from the GSEA database (Table S2). Based on these genes, we classified the GEO set (GSE39084 + GSE39582) using the NMF package. The optimal clustering number was chosen according to the $k$ value, which was determined by the cophenetic correlation coefficient. In this study, the cophenetic correlation coefficient started to decrease, when the $k$ value was 2 (Figure 2(a)). Then, we evaluated the differential expressions of 22 prognostic hypoxia-related genes in different subgroups. The results showed that most of the hypoxia-related genes were increasingly expressed in Cluster2 (Figure 2(b)). Meanwhile, the distributions of patients from different subgroups were separated clearly via PCA and t-SNE analyses (Figures 2(c) and 2(d)). Combined with these results, we finally decided to classify 88 dMMR CC patients into 2 different subgroups. Cluster1 was defined as normoxia subgroup (NS), and Cluster2 was defined as hypoxia subgroup (HS).

The clinicopathological features between different subgroups were also analyzed (Table S3). We found that patients in NS were younger ($p < 0.001$) and had better pathological stages ($p = 0.038$). In the TCGA COAD cohort, the pathological stage and $M$ were also better in NS. In the combined GEO cohort, all 88 patients with CC had complete follow-up information. We used K-M analysis to compare their prognosis between NS and HS. The results showed that the OS of NS was significantly better than that of HS ($p = 0.034$) (Figure 3(a)). Interestingly, none of the patients in NS had died during follow-up. In coincidence with our findings, previous studies also found that pathological stage and age were closely associated with the OS/DFS of patients with colorectal cancer (CRC) [22, 23].

After the distinct clinical features of the two subgroups were uncovered, we decided to investigate whether differences also existed on gene expression and functional levels. We found that 198 genes were differentially expressed ($|\log_{2} FC| > 1$ and FDR $< 0.05$) between NS and HS (Figure 3(b)). Among them, the expression of 153 genes was significantly lower and the expression of other genes was higher in NS, compared to HS. Meanwhile, 12 hypoxia-related genes, including MAFF, MT1E, MT2A, et al., were decreasingly expressed in NS, and only one hypoxia-related gene, named SELENBP1, was increasingly expressed in NS. This result was consistent with the clustering result shown in Figure 2(b), which indicated that most hypoxia-related genes were decreasingly expressed in NS compared to those in HS. Based on the KEGG analysis, we found that these DEGs were involved in inflammation-related (cytokine-cytokine receptor interaction, chemokine signaling pathway, and NF-κB signaling pathway) and tumor-related (TNF signaling pathway) pathways (Figure 3(c)). Similarly, the result of
biological processes (Figure 3(d)), cellular component (Figure 3(e)), and molecular function (Figure 3(f)) analysis using GO showed that these DEGs were associated with inflammatory function, including response to interleukin-1, cytokine activity, chemokine activity, CXCR chemokine receptor binding, and others. Taken together, these results indicated that the hypoxia condition in TME would not only regulate the biological behavior of tumor cells but also
change the metabolism and secretion of immune cells. These findings were also supported by previous studies [24–26]. They found that the deprivation of oxygen and glucose caused by the tumor and stromal cells would induce exhaustion and dysfunction of TILs, subsequently creating an immunosuppressive TME.

3.2. Different Tumor-Immune Microenvironments between Subgroups. Because the survival status was significantly different between the two subgroups and the functions of the DEGs were enriched in inflammatory pathways, we decided to investigate whether the TIME between the two subgroups was distinct. Through analysis of CIBERSORTx, we found that the resting of CD8+ T cells, CD4+ T cells activated, M1 macrophages, and dendritic cells resting were significantly more in NS (Figure 4(a)). We supposed that the relative normoxia TME might be conducive to the infiltration of cytotoxic T cells and the polarization of macrophages into the M1 type. Previous studies suggested that HIF-1, a major factor elevated in hypoxia zone and PD-L1, could directly regulate the differentiation of tumor-associated macrophages (TAMs) and convert them into polarized M2 type, which often played an immunosuppressive role in TME and led to drug resistance of immunotherapy [27–29].

To more deeply investigate the differences of TIME, we also evaluated the expressions of immune-related genes (obtained from the Tracking Tumor Immunophenotype database), immune checkpoint molecules, and C-X-C motif chemokines between two subgroups. The result showed that most interferon (IFN)-related genes were increasingly expressed in NS, which followed the previous result that CD8+ and CD4+ T cells were significantly richer in NS (Figure 4(b)). Despite PDCD1, also known as programmed
cell death 1 (PD-1), all the other immune checkpoint molecules were decreasingly expressed in NS (Figure 4(c)). Although PD-1 was expressed by types of immune cells, including B cells, natural killer cells, innate lymphoid cells, and myeloid cells, its expression mainly occurred on T cells [30]. In our study, we found that most types of T cells, including CD8+, CD4+ memory activated, follicular helper, and regulatory T cells, were enriched in NS compared to those in HS. These might be associated with the increased expression of PD-1 in NS. Similar to the result shown in the

Figure 3: The differences in survival status and functional enrichment between the two subgroups. (a) Kaplan–Meier curve showed that NS had significantly better OS than HS. (b) There were 198 DEGs between two subgroups. Among these DEGs, 13 genes were hypoxia related, which were shown with their names. (c) The KEGG signaling pathways showed that these DEGs enriched in cytokine, TNF, chemokine, and NF-κB pathways. Biological processes (d), cellular component (e), and molecular function (f) also showed similar results with KEGG analysis.
Figure 4: Continued.
expression of immune-related genes, immune checkpoint molecules, and chemokines. The result of CIBERSORTx analysis showed that NS had higher infiltration of CD4+ T cells, CD8+ T cells, and M1 macrophages and lower infiltration of M2 macrophages and neutrophils. The heatmap revealed different expressions of immune-related genes between two subgroups. Despite PDCD1, all the other immune checkpoint molecules were increasingly expressed in HS. Most of the chemokines were also increasingly expressed in HS. *represents \( p < 0.05 \), **represents \( p < 0.01 \), ***represents \( p < 0.001 \), and ****represents \( p < 0.0001 \).

Next, we investigated the correlation of the expression of these genes. The expression correlation plot suggested that all three genes were positively expressed (\( p < 0.001 \)) (Figure 5(b)). Since all three genes were increasingly expressed in HS in both GEO and TCGA cohorts, we supposed that these genes would be negatively related to the OS and the infiltration of immune cells. Therefore, we evaluated the correlation using K-M and Spearman’s analyses (Figures 5(c)–5(h)). The results showed that increasing expression of three genes was significantly associated with poor OS status (Figures 5(c), 5(e), and 5(g)). Meanwhile, all 3 genes were negatively related to the infiltration of CD4+ T cells and dendritic cells and positively related to the infiltration of neutrophils. Previous studies also identified that higher infiltration of neutrophils was consistent with poor survival status in numerous types of cancer [33–35]. Moreover, the expression of MAFF was negatively associated with the infiltration of CD8+ T cells. Since MAFF was increasingly expressed in HS, which also had fewer infiltrations of CD8+ T cells, CD4+ T cells, and M1 macrophages, and more infiltration of M2 macrophages and neutrophils, it revealed that MAFF might be the potentially important regulatory gene in hypoxia TIME.

3.4. Construction of Prognostic Model Based on Hypoxia-Related Genes. The previous analyses identified that dMMR CC patients could be classified into hypoxia and normoxia subgroups. These subgroups showed different expressions of hypoxia-related genes, functional enrichments, TIME, and prognosis. Three genes, namely, MT1E, MT2A, and MAFF, were differentially expressed between NS and HS in both GEO and TCGA cohorts. Next, we wondered whether a prognostic model based on these genes could be built for clinical application.

Initially, 3 genes were included. Through Lasso Cox regression analysis, 2 genes, such as MT2A and MAFF, were filtered for the construction of this prognostic model (Figures 6(a) and 6(b)). The formula of the prognostic model was shown as follows:

\[
\text{Survival time} = \frac{1}{\lambda_{0}(t)} \exp\left(\beta_{1}\text{MT1E} + \beta_{2}\text{MT2A} + \beta_{3}\text{MAFF}\right)
\]

\[
\lambda_{0}(t) = \exp(\beta_{0})
\]

Figure 4: The analyses of TIME identified that two subgroups had a quite different infiltration of immune cells and the expression of immune-related genes, immune checkpoint molecules, and chemokines. (a) The result of CIBERSORTx analysis showed that NS had higher infiltration of CD4+ T cells, CD8+ T cells, and M1 macrophages and lower infiltration of M2 macrophages and neutrophils. (b) The heatmap revealed different expressions of immune-related genes between two subgroups. (c) Despite PDCD1, all the other immune checkpoint molecules were increasingly expressed in HS. (d) Most of the chemokines were also increasingly expressed in HS. *represents \( p < 0.05 \), **represents \( p < 0.01 \), ***represents \( p < 0.001 \), and ****represents \( p < 0.0001 \).

3.3. Analyses for Hypoxia-Related Hub Genes. In previous analyses, we found that there were 198 DEGs between NS and HS in GEO sets and 81 DEGs in the TCGA COAD cohort. We wondered whether there were intersections between DEGs in GEO sets and DEGs in the TCGA cohort. The Venn plot showed that 5 genes were differentially expressed in both GEO sets and TCGA cohort (Figure 5(a)). Among them, 3 genes, namely, MT1E, MT2A, and MAFF, were hypoxia related.
Figure 5: Continued.
Figure 5: The analyses about three hub genes, such as MT1E, MT2A, and MAFF. (a) Three hub genes were the intersection of the DEGs of GEO and TCGA sets and 200 hypoxia-related genes. (b) The expression of these genes was significantly positively correlated. The Kaplan-Meier curves of MT1E (c), MT2A (e), and MAFF (g) showed that higher expression of these genes was significantly associated with poorer prognosis of dMMR CC patients. The spearman correlation plots of MT1E (d) and MT2A (f) showed similar results: the expression of MT1E and MT2A was negatively related to the infiltration of CD8+ T cells. (h) Meanwhile, the expression of MAFF was negatively associated with the infiltration of neutrophils, CD4+ T cells, CD8+ T cells, dendritic cells, and M2 macrophages, and positively associated with the infiltration of M2 Macrophages. * represents \( p < 0.05 \), ** represents \( p < 0.01 \), *** represents \( p < 0.001 \), and **** represents \( p < 0.0001 \).

\[
\text{Risk score} = 0.861 \times MT2A + 0.426 \times MAFF \text{ (the median of risk score was 13.551).}
\]

We defined groups with higher scores than the median as a high-risk group, while lower scores than the median as a low-risk group. From the risk plot (Figure 6(c)) and K-M curve (Figure 6(e)), we found that the low-risk group had a lower ratio of dead cases and a significantly better prognosis \( (p = 0.007) \). Meanwhile, the low-risk group had lower expression of hub genes, better pathological \( N \), \( T \), stage, younger age, and more cases of female patients and distal colon tumors (Figure 6(d)). Through univariate and multivariate Cox analyses, we identified that the prognostic model was the independent predictor for dMMR CC patients (Figures 6(f) and 6(g)).

The clinical characteristics of the low-risk group were distinct from the high-risk group, including the proportion of gender, age, tumor location, and pathological features. Our findings were supported by previous studies \[36, 37\]. They also found that male patients, right-side tumors, and poor pathological features were potential risk factors for recurrence and prognosis of patients with colorectal cancer (CRC). On the other hand, it also indicated that two genes, namely, MT2A and MAFF, might act an important role in the development and progression of colon cancer and the prognostic model based on these genes would be valuable for clinical application.

3.5. Calibration and Visualization of the Prognostic Model. We used ROC and the calibration model to evaluate the discrimination ability and stability of this prognostic model. The result of ROC analysis suggested that this model had a good discrimination ability to predict 1- (AUC = 72.3%), 3- (AUC = 72.9%), and 5-year (78.6%) OS for dMMR CC patients (Figure 7(a)). The apparent and bias-corrected curves were close to the ideal curve in the calibration plot, indicating good stability and consistency of this prognostic model (Figure 7(b)).

Subsequently, we developed a nomogram for clinical application. Along with the risk score of the prognostic model, it also contained pathological \( T \), \( N \), \( M \), stage, and age (Figure 7(c)). Its usage was quite simple and user-friendly, which was divided into three steps. First, each factor would be read and would have a different point according to the point scale. Second, the point of each factor would be added up to have a total point. It would be identified on the total point scale. Finally, the OS of dMMR CC patients would be represented in the probability scale, based on the total point calculated in the previous step.

Moreover, to make the diagnostic model more convenient to use, we developed an online dynamic nomogram (Figure 7(d)). It could simplify the four-step usage into a two-step usage. First, different values of each clinicopathological factor could be chosen in the drop-down menu. Then, the user only had to click the predict button, and the OS probability of the patients would be calculated automatically based on the prognostic model. Meanwhile, a forest plot with a 95% confidence interval (CI) would be simultaneously visualized.

4. Discussion

In this study, based on hypoxia-related gene signature, we have classified dMMR CC patients into 2 subgroups. Most hypoxia-related genes in HS were increasingly expressed, compared to those in NS. Therefore, we considered that NS
Figure 6: Continued.
was a normoxia subgroup and HS was a hypoxia subgroup. The TIME of NS was quite different from that of HS, showing that the infiltration of most TILs was significantly higher in NS. Meanwhile, it also had lower expressions of the immune checkpoint molecules and chemokines. These results indicated that NS might have a relative normoxia TME, which could promote the infiltration of TILs, thus resulting in a better prognosis. Moreover, we also developed a prognostic model based on two hypoxia-related genes, namely, MT2A and MAFF. It showed a stable and consistent predicting ability, also indicating the close association between hypoxia and prognosis of patients with dMMR CC. Finally, we identified that MAFF might be a potentially important regulatory gene involved in the hypoxia TME of dMMR CC patients.

The MSI/dMMR CC patients were initially considered to have high levels of TMB and neoantigens, which could induce sustained self-immune responses and ensure the curative effect of immunotherapy [8]. At present, immune checkpoint inhibitors (ICIs) have been approved by FDA to treat advanced MSI/dMMR CC patients [38]. However, a previous study has shown that there were still nearly 60% MSI/dMMR that were not responsive to ICIs, indicating that the TIME was variable even among MSI/dMMR patients [39]. Therefore, the urgency is to uncover the underlying mechanism and identify the most responsive patients, thus improving therapeutic efficiency.

In this study, we found that even among patients with CC with dMMR status, there was variable TIME, which was considered to be closely associated with the therapeutic efficiency of ICIs and prognosis. A previous study suggested that alterations and evolutions had always existed inside the TME of the tumors treated with ICIs [40]. Meanwhile, exhaustion and deletion of tumor-specific CD8+ T cells could significantly impair the antitumor effect of ICIs and induce drug resistance [41]. These findings highlight the importance of CD8+ T cells involved in the therapy of ICIs. However, the uncontrolled growth of tumor cells creates hypoxia and malnutritional TME. It will significantly impair the metabolism and colonization of CD8+ T cells, thus inducing tumor progression and drug resistance of ICIs [10]. In this study, patients in the normoxia subgroup had significantly higher infiltration of CD8+ and CD4+ T cells. We supposed that these patients might be more responsive to ICIs, and the better prognosis of them might be partially associated with higher infiltration of TILs. Interestingly, in NS, besides higher infiltration of TILs, there was also significantly lower infiltration of neutrophils. A previous study suggested that neutrophils could act as either a tumor suppressor or a promoter, depending on tumor type and stage [42]. Later in the progression of tumors, neutrophils would promote tumor growth by releasing vascular endothelial growth factor (VEGF) to stimulate angiogenesis [42]. In this study, we also found that the expression of VEGF was significantly higher in HS accompanied by the higher infiltration of neutrophils. In colorectal cancer (CRC), higher infiltration of tumor-infiltrating neutrophils was positively associated with higher histological grade, advanced pathological stage, and poorer recurrence-free survival [34]. Besides, in both GEO sets and TCGA cohort, we have identified higher infiltration of M1 and lower infiltration of M2 in NS. High-mobility group box 1 protein (HMGB1), increasingly expressed in hypoxia TME and closely associated with the development of CC, has been proven to be related to macrophage colonization, especially for the M2 type [43]. These M2 macrophages would secrete high levels of VEGF and TNF-α, which was also proven in this study in Figure 3(b), and consequently promote the progression and metastasis of tumors [44, 45].

PD-1, a type of inducible membrane protein, is often upregulated with the activation of CD8+ T cells via NFATc1, Notch, and STAT pathways [46–48]. However, tumor-infiltrating CD8+ T cells will experience distinct differential reprograms. Some of them subsequently acquire an exhaustion type, due to the hypoxia, acidic, and malnutritional TME. During the reprogramming process, these cells will elevate the inhibitory receptors, such as PD-1 [49]. These findings highlight the importance of PD-1 induction in CD8+ T cells in the TME and thus open a door to PD-1 inhibitor with therapeutic effect in clinical application. In this study, we found that PDCD1, another symbol of PD-1, was increasingly expressed in NS. Except for PD-1, all the other immune checkpoint molecules, including PD-L1, CTLA4, et al., declined in NS. Previous studies also identified...
Figure 7: The validation and visualization of the prognostic model. (a) The ROC curve showed that the discrimination of the model was valuable for the prediction of 1-, 3-, and 5-year OS. (b) The calibration plot suggested that the performance of this model was stable. (c) The nomogram was built based on the risk score and the clinicopathological features, including age, pathological T, N, M, and stage. (d) The shiny app was developed based on the prognostic model for convenient clinical application.
that hypoxia could induce the high expression of immune checkpoint molecules, such as indoleamine 2,3-dioxygenase (IDO) and PD-L1 [50, 51]. The expression of immune checkpoint molecules might be negatively associated with the infiltration of TILs and the prognosis in types of cancers [7, 52, 53].

In hypoxia TME, CXC chemokines are mainly secreted by tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) via hypoxia-inducible factor (HIF)/nuclear factor xB (NF-xB) pathway [54, 55]. Subsequently, these activated CXC chemokines will promote the progression and metastasis of cancer via numerous promtumor properties. Seven CXC chemokines reported in this study, such as CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL8, and CXCL16, are all angiogenic [56–59]. High expression of these chemokines will cause neovascularization, thus promoting tumor invasion and metastasis [60]. In this study, we also found that the hypoxia subgroup had a higher expression of CXC chemokines, which might be related to the poorer prognosis of this subgroup.

In this study, three genes, namely, MT1E, MT2A, and MAFF, were the intersection of GEO-DEGs, TCGA-DEGs, and hypoxia-related gene list. Two of them, namely, MT2A and MAFF, were included in the construction of the prognostic model for clinical application. Metallothioneins (MTs), a family of low molecular weight proteins, play an important role in the regulation of the cellular homeostasis of zinc and copper [61]. Among types of MTs, MT1 and MT2 are the most widely distributed isoforms, which were commonly found in many tissues, especially in the liver and kidneys [62]. MTs may be tightly involved in carcinogenesis, including tumor growth, differentiation, angiogenesis, and metastasis [63]. Meanwhile, MTs can also be involved in the process of TME remodeling and immune escape by binding to the plasma membrane of TILs and changing their immunomodulatory functions [64]. High levels of MTs released in the extracellular environment were proven to be closely associated with immunosuppression, tumor aggressiveness, and metastasis in numerous cancers [65–67]. Another hub gene, MAFF, is also hypoxia related and has been proven to be tightly associated with invasion and metastasis of cancer via HIF/NF-xB pathway [68]. Meanwhile, it has also been identified to promote M2 polarization in TAMs, indicating its role involved in TME remodeling and ICI therapy [69]. In this study, we also found that higher expression of MT1E, MT2A, and MAFF was related to the poorer infiltration of CD8+ T cells and poorer prognosis of dMMR CC patients. In a further study, we decided to focus on these genes and their roles involved in the development and progression of CC.

Moreover, we also developed a prognostic model, as well as a nomogram and a shiny app, based on the hypoxia-related genes. Numerous studies have also constructed similar prognostic models in types of cancer, such as osteosarcoma [70], breast [71], renal [72], and lung cancer [73]. In all these studies, despite different genes, patients with higher expression of hypoxia-related genes had either poorer pathological stage, infiltration of immune cells, or survival status, highlighting the potential of hypoxia genes in clinical application.

This study has several limitations: (1) due to limiting data resources of patients with CC with dMMR, the sample size of this study was small, which might induce selection bias; (2) during the validation process of the prognostic model, external validation set was not available, thus inducing risks of instability of the model; (3) it is only a bioinformatic study without experiment in vitro/vivo; however, we have identified three hypoxia-related hub genes that played an important role in TIME and prognosis of dMMR CC patients. In a further study, we will focus on these genes and their biological functions in the development and progression of dMMR CC.

In summary, we have classified dMMR CC patients into hypoxia and normoxia subgroups and revealed their different TIMEs. We found that the hypoxia subgroup had lower infiltration of TILs, more expression of immune checkpoint molecules and chemokines, and a poorer prognosis. Based on all the evidence, we supposed that hypoxia TME might be potentially associated with ICI resistance in dMMR CC patients. Subsequently, we identified two hub genes and will focus on them in further study. Moreover, we have developed a prognostic model. Based on it, a nomogram and a shiny app were constructed for clinical application.

### Data Availability

The generated and analyzed databases of the present study are freely available in GEO (https://www.ncbi.nlm.nih.gov/geo/) and TCGA (https://portal.gdc.cancer.gov/) databases.

### Conflicts of Interest

The authors declare no conflicts of interest.

### Authors’ Contributions

Yixin Xu conceived and designed the study and wrote the manuscript (original draft). Jujie Hu and Can Cao collected the original data. Mili Zhang analyzed the data. Youdong Liu, Shanshan Wei, Hannan Chen, and Ziyan Zhu performed the data visualization. Liang Yu and Jikun Li reviewed and edited the manuscript. All authors agreed to be accountable for the content of this work. All authors contributed to the article and approved the submitted version.

### Acknowledgments

The authors would like to thank Jing Yang and Jieqi Mao for their help during the process of this study. This study was funded by the Changzhou SciTech Program (no. CJ20210017), the Clinical Technology Development Foundation of Jiangsu University (no. JLY2021022), the National Natural Science Foundation of China (NSFC) (nos. 81673034 and 82072643), and the Shanghai Natural Science Foundation (nos. 19ZR1441000 and 21ZR1452100).
Supplementary Materials

Supplementary 1. Table S1: the list of 200 hypoxia-related genes. Supplementary 2. Table S2: the list of 22 hypoxia-related genes with prognostic value. Supplementary 3. Table S3: different clinicopathological features between normoxia and hypoxia subgroups in GEO and TCGA sets. Supplementary 4. Figure S1: the validation of the hypoxia-related gene clustering method in the TCGA COAD cohort. (a) The heatmap showed different expressions of 22 prognostic hypoxia genes between the two subgroups. (b) There were 98 DEGs between two subgroups. Among them, 6 genes were hypoxia related. (c) The result of CIBERSORTx analysis showed different infiltration of immune cells between two subgroups. (d) The heatmap showed different expressions of immune-related genes between two subgroups. Despite PDCD1, all the other immune checkpoint molecules (e) and chemokines (f) were increasingly expressed in HS. (Supplementary Materials)

References

[1] H. Sung, J. Ferlay, R. L. Siegel et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: A Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209–249, 2021.
[2] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.
[3] A. J. Franke, W. P. Skelton, J. S. Starr et al., “Immunotherapy for colorectal cancer: a review of current and novel therapeutic approaches,” Journal of the National Cancer Institute: Journal of the National Cancer Institute, vol. 111, no. 11, pp. 1131–1141, 2019.
[4] A. A. Bielska, W. K. Chatila, H. Walch et al., “Tumor mutational burden and mismatch repair deficiency discordance as a mechanism of immunotherapy resistance,” Journal of the National Comprehensive Cancer Network, vol. 19, no. 2, pp. 130–133, 2021.
[5] R. Cristescu, J. Lee, M. Nebozhyn et al., “Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes,” Nature Medicine, vol. 21, no. 5, pp. 449–456, 2015.
[6] W. Lin, S. Wu, X. Chen et al., “Characterization of hypoxia signature to evaluate the tumor immune microenvironment and predict prognosis in glioma groups,” Frontiers in Oncology, vol. 10, p. 796, 2020.
[7] J. P. Pei, C.-D. Zhang, M. Yusupu, C. Zhang, and D.-Q. Dai, “Screening and validation of the hypoxia-related signature of evaluating tumor immune microenvironment and predicting prognosis in gastric cancer,” Frontiers in Immunology, vol. 12, p. 705511, 2021.
[8] V. Randrian, C. Evrard, and D. Tougeron, “Microsatellite instability in colorectal cancers: carcinogenesis, neo-antigens, immune-resistance and emerging therapies,” Cancers, vol. 13, no. 12, p. 3063, 2021.
[9] B. I. Reinfeld, M. Z. Madden, M. M. Wolf et al., “Cell-programmed nutrient partitioning in the tumour microenvironment,” Nature, vol. 593, no. 7858, pp. 282–288, 2021.
[10] M. Reina-Campos, N. E. Scharpung, and A. W. Goldrath, “CD8+ T cell metabolism in infection and cancer,” Nature Reviews Immunology, vol. 21, no. 11, pp. 718–738, 2021.
[11] A. L. Harris, “Hypoxia-a key regulatory factor in tumour growth,” Nature Reviews Cancer, vol. 2, no. 1, pp. 38–47, 2002.
[12] K. DePeau and G. M. Delgoffe, “Metabolic barriers to cancer immunotherapy,” Nature Reviews Immunology, vol. 21, no. 12, pp. 785–797, 2021.
[13] I. Kaymak, K. S. Williams, J. R. Cantor, and R. G. Jones, “Immunometabolic interplay in the tumor microenvironment,” Cancer Cell, vol. 39, no. 1, pp. 28–37, 2021.
[14] A. Brandl, K. Singer, G. E. Kochl et al., “LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells,” Cell Metabolism, vol. 24, no. 5, pp. 657–671, 2016.
[15] E. Reznik, A. Luna, B. A. Aksoy et al., “A landscape of metabolic variation across tumor types,” Cell Systems, vol. 6, no. 3, pp. 301–313, 2018.
[16] A. R. Lim, W. K. Rathmell, and J. C. Rathmell, “The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy,” Elife, vol. 9, 2020.
[17] A. Liberzon, A. Subramanian, R. Pinchback, H. Thorvaldsdottir, P. Tamayo, and J. P. Mesirov, “Molecular signatures database (MSigDB) 3.0,” Bioinformatics, vol. 27, no. 12, pp. 1739–1740, 2011.
[18] A. Liberzon, C. Birger, H. Thorvaldsdottir, M. Ghandi, J. P. Mesirov, and P. Tamayo, “The molecular signatures database hallmark gene set collection,” Cell Systems, vol. 1, no. 6, pp. 417–425, 2015.
[19] L. Xu, C. Deng, B. Pang et al., “TIP: a web server for resolving tumor Immunophenotype profiling,” Cancer Research, vol. 78, no. 23, pp. 6575–6580, 2018.
[20] R. Gaujoux and C. Seoighe, “A flexible R package for non-negative matrix factorization,” BMC Bioinformatics, vol. 11, no. 1, p. 367, 2010.
[21] A. M. Newman, C. B. Steen, C. L. Liu et al., “Determining cell type abundance and expression from bulk tissues with digital cytometry,” Nature Biotechnology, vol. 37, no. 7, pp. 773–782, 2019.
[22] L. Gately, A. Jalali, C. Semira et al., “Stage dependent recurrence patterns and post-recurrence outcomes in non-metastatic colon cancer,” Acta Oncologica, vol. 60, no. 9, pp. 1106–1113, 2021.
[23] L. Zhu, H. Sun, G. Tian et al., “Development and validation of a risk prediction model and nomogram for colon adenocarcinoma based on methylation-driven genes,” Aging, vol. 13, no. 12, pp. 16600–16619, 2021.
[24] R. D. Leone and J. D. Powell, “Metabolism of immune cells in cancer,” Nature Reviews Cancer, vol. 20, no. 9, pp. 516–531, 2020.
[25] C.-H. Chang, J. Qiu, D. O’Sullivan et al., “Metabolic competition in the tumor microenvironment is a driver of cancer progression,” Cell, vol. 162, no. 6, pp. 1229–1241, 2015.
[26] G. Andrejeva and J. C. Rathmell, “Similarities and distinctions of cancer and immune metabolism in inflammation and tumors,” Cell Metabolism, vol. 26, no. 1, pp. 49–70, 2017.
[27] M. Z. Noman, G. Desantis, B. Janji et al., “PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation,” Journal of Experimental Medicine, vol. 211, no. 5, pp. 781–790, 2014.
[28] A. J. Boutillier and S. F. Elsawa, “Macrophage polarization states in the tumor microenvironment,” International Journal of Molecular Sciences, vol. 22, no. 13, p. 6995, 2021.
[29] X. Jing, F. Yang, C. Shao et al., “Role of hypoxia in cancer therapy by regulating the tumor microenvironment,” Molecular Cancer, vol. 18, no. 1, p. 157, 2019.
[30] A. H. Sharpe and K. E. Pauken, “The diverse functions of the PD1 inhibitory pathway,” Nature Reviews Immunology, vol. 18, no. 3, pp. 153–167, 2018.
[31] J. Korbecki, K. Kojder, P. Kapczuk et al., “The effect of hypoxia on the expression of CXC chemokines and CXC chemokine receptors-A review of literature,” International Journal of Molecular Sciences, vol. 22, no. 2, p. 843, 2021.

[32] E. Goleva, T. Lyubchenko, L. Kraehenbuehl, M. E. Lacouture, D. Y. M. Leung, and J. A. Korn, “Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy,” Annals of Allergy, Asthma, & Immunology, vol. 126, no. 6, pp. 630–638, 2021.

[33] C. Qian, R. Cai, W. Zhang et al., “Neutrophil-lymphocyte ratio and circulating tumor cells counts predict prognosis in gastrointestinal cancer patients,” Frontiers in Oncology, vol. 11, p. 710704, 2021.

[34] B. G. Rottmann, N. Patel, M. Ahmed et al., “Clinicopathological significance of neutrophil-rich colorectal carcinoma,” Journal of Clinical Pathology, vol. 2021, p. jcclinpath, 2021.

[35] R. Anderson, A. G. Blidner, and B. L. Rapoport, “Frontiers in pharmacology: review manuscript targeting of the neutrophil as an adjunctive strategy in non-small cell lung cancer,” Frontiers in Pharmacology, vol. 12, p. 676399, 2021.

[36] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer statistics, 2021,” CA: A Cancer Journal for Clinicians, vol. 71, no. 1, pp. 7–33, 2021.

[37] M. K. Barton, “Primary tumor location found to impact prognosis and response to therapy in patients with metastatic colorectal cancer,” CA: A Cancer Journal for Clinicians, vol. 67, no. 4, pp. 259–260, 2017.

[38] S. Emambux, G. Tachon, A. Junca, and D. Tougeron, “Results and challenges of immune checkpoint inhibitors in colorectal cancer,” Expert Opinion on Biological Therapy, vol. 18, no. 5, pp. 561–573, 2018.

[39] D. T. Le, J. N. Uram, H. Wang et al., “PD-1 blockade in tumors with mismatch-repair deficiency,” New England Journal of Medicine, vol. 372, no. 26, pp. 2509–2520, 2015.

[40] G. Germano, S. Lamba, G. Rospo et al., “Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth,” Nature, vol. 552, no. 7683, pp. 116–120, 2017.

[41] C.-C. S. Pai, J. T. Huang, X. Lu et al., “Clonal deletion of tumor-specific T cells by interferon-γ confers therapeutic resistance to combination immune checkpoint blockade,” Immunity, vol. 50, no. 2, pp. 477–492, 2019.

[42] N. M. Anderson and M. C. Simon, “The tumor microenvironment,” Current Biology, vol. 30, no. 16, pp. R921–R925, 2020.

[43] T. Shekarian, S. Valsesia-Wittmann, J. Brody et al., “Pattern recognition receptors: immune targets to enhance cancer immunotherapy,” Annals of Oncology, vol. 28, no. 8, pp. 1756–1766, 2017.

[44] Y. Wu, S. Yang, J. Ma et al., “Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level,” Cancer Discovery, p. candisc.0316.2021, 2021.

[45] Y. Xia, L. Rao, H. Yao, Z. Wang, P. Ning, and X. Chen, “Engineering macrophages for cancer immunotherapy and drug delivery,” Advanced Materials, vol. 32, no. 40, p. 2002054, 2020.

[46] V. A. Boussiotis, “Molecular and biochemical aspects of the PD-1 checkpoint pathway,” New England Journal of Medicine, vol. 375, no. 18, pp. 1767–1778, 2016.

[47] C. Li, W. Li, J. Xiao et al., “ADAP and SKAP 55 deficiency suppresses PD-1 expression in CD8 + cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy,” EMBO Molecular Medicine, vol. 7, no. 6, pp. 754–769, 2015.

[48] M. Mathieu, N. Cotta-Grand, J. F. Daudelin, P. Thébault, and N. Labrecque, “Notch signaling regulates PD-1 expression during CD8 + T-cell activation,” Immunology & Cell Biology, vol. 91, no. 1, pp. 82–88, 2013.

[49] M. Foroutan, R. Molania, A. Pfefferle et al., “The ratio of exhausted to resident infiltrating lymphocytes is prognostic for colorectal cancer patient outcome,” Cancer Immunology Research, vol. 9, no. 10, pp. 1125–1140, 2021.

[50] Y. Li, S. P. Patel, J. Roszik, and Y. Qin, “Hypoxia-Driven immunosuppressive metabolites in the tumor microenvironment: new approaches for combinational immunotherapy,” Frontiers in Immunology, vol. 9, p. 1591, 2018.

[51] L. Xing, J.-H. Gong, Y. Wang et al., “Hypoxia alleviation-triggered enhanced photodynamic therapy in combination with Ido inhibitor for preferable cancer therapy,” Biomaterials, vol. 206, pp. 170–182, 2019.

[52] W. Zhong, H. Zhong, F. Zhang, C. Huang, Y. Lin, and J. Huang, “Characterization of hypoxia-related molecular subtypes in clear cell renal cell carcinoma to aid immunotherapy and targeted therapy via multi-omics analysis,” Frontiers in Molecular Biosciences, vol. 8, p. 684050, 2021.

[53] X. Yang, X. Weng, Y. Yang et al., “A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer,” Aging, vol. 13, no. 15, pp. 19486–19509, 2021.

[54] H.-Y. Fang, R. Hughes, C. Murdoch et al., “Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia,” Blood, vol. 114, no. 4, pp. 844–859, 2009.

[55] J. Wang, F. Yu, X. Jia et al., “MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth,” International Journal of Cancer, vol. 136, no. 6, pp. E602–E613, 2015.

[56] R. M. Strieter, P. J. Polverini, S. L. Kunkel et al., “The functional role of the ELR motif in CXC chemokine-mediated angiogenesis,” Journal of Biological Chemistry, vol. 270, no. 45, pp. 27348–27357, 1995.

[57] R. Salcedo, J. H. Resau, D. Halverson et al., “Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells,” The FASEB Journal, vol. 14, no. 13, pp. 2055–2064, 2000.

[58] J. Heidemann, H. Ogawa, M. B. Dwinnell et al., “Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2,” Journal of Biological Chemistry, vol. 278, no. 10, pp. 8508–8515, 2003.

[59] J. Korbecki, K. Bajdak-Rusinek, P. Kupnicka et al., “The role of CXCL16 in the pathogenesis of cancer and other diseases,” International Journal of Molecular Sciences, vol. 22, no. 7, p. 3490, 2021.

[60] H. T. T. Do, C. H. Lee, and J. Cho, “Chemokines and their receptors: multifaceted roles in cancer progression and potential value as cancer prognostic markers,” Cancers, vol. 12, no. 2, p. 287, 2020.

[61] T. Zhao, Q. Huang, Y. Su, W. Sun, Q. Huang, and W. Wei, “Zinc and its regulators in pancreas,” Inflammopharmacology, vol. 27, no. 3, pp. 453–464, 2019.

[62] H. Gungor and H. Kara, “Effects of selenium, zinc, insulin and metallothionein on cadmium-induced oxidative stress and metallothionein gene expression levels in diabetic rats,” Journal of Basic and Clinical Physiology and Pharmacology, vol. 31, no. 2, 2020.

[63] M. Si and J. Lang, “The roles of metallothioneins in carcinogenesis,” Journal of Hematology & Oncology, vol. 11, no. 1, p. 107, 2018.
[64] C. Hübner and H. Haase, "Interactions of zinc- and redox-signaling pathways," *Redox Biology*, vol. 41, p. 101916, 2021.

[65] E. Emri, K. Egervari, T. Varvolgyi et al., "Correlation among metallothionein expression, intratumoral macrophage infiltration and the risk of metastasis in human cutaneous malignant melanoma," *Journal of the European Academy of Dermatology and Venereology*, vol. 27, no. 3, pp. e320–e327, 2013.

[66] M. Dutsch-Wicherek, A. Lazar, R. Tomaszewska, W. Kazmierczak, and L. Wicherek, "Analysis of metallothionein and vimentin immunoreactivity in pharyngeal squamous cell carcinoma and its microenvironment," *Cell and Tissue Research*, vol. 352, no. 2, pp. 341–349, 2013.

[67] M. Dutsch-Wicherek, A. Lazar, and R. Tomaszewska, "The potential role of MT and vimentin immunoreactivity in the remodeling of the microenvironment of parotid adenocarcinoma," *Cancer Microenvironment*, vol. 4, no. 1, pp. 105–113, 2010.

[68] E. J. Moon, S. S. Mello, C. G. Li et al., "The HIF target MAFF promotes tumor invasion and metastasis through IL11 and STAT3 signaling," *Nature Communications*, vol. 12, no. 1, p. 4308, 2021.

[69] J. R. Conejo-Garcia and P. C. Rodriguez, "c-Maf: a bad influence in the education of macrophages," *Journal of Clinical Investigation*, vol. 130, no. 4, pp. 1629–1631, 2020.

[70] F. Jiang, X.-L. Miao, X.-T. Zhanget al., "A hypoxia gene-based signature to predict the survival and affect the tumor immune microenvironment of osteosarcoma in children," *Journal of Immunology Research*, vol. 2021, Article ID 5523832, 13 pages, 2021.

[71] Y. Zhao, L. Liu, J. Zhao et al., "Construction and verification of a hypoxia-related 4-lncRNA model for prediction of breast cancer," *International Journal of General Medicine*, vol. 14, pp. 4605–4617, 2021.

[72] H. Chen, Y. Pan, X. Jin, and G. Chen, "Identification of a four hypoxia-associated long non-coding RNA signature and establishment of a nomogram predicting prognosis of clear cell renal cell carcinoma," *Frontiers in Oncology*, vol. 11, p. 713346, 2021.

[73] L. Liu, C. Wang, S. Li et al., "ERO1L is a novel and potential biomarker in lung adenocarcinoma and shapes the immune-suppressive tumor microenvironment," *Frontiers in Immunology*, vol. 12, p. 677169, 2021.